- 1 COVID-19 mRNA Vaccination in Lactation: Assessment of adverse effects and
- 2 transfer of anti-SARS-CoV2 antibodies from mother to child
- 4 Yarden Golan, Ph.D.¹, Mary Prahl, M.D.^{2,3}, Arianna G. Cassidy, M.D.⁴, Caryl Gay Ph.D.
- ⁵, Alan H.B. Wu, Ph.D. ⁶, Unurzul Jigmeddagva, M.D. ⁷, Christine Y. Lin⁴, Veronica J.
- 6 Gonzalez, M.D.⁴, Emilia Basilio, M.D, M.P.H⁴, Lakshmi Warrier⁸, Sirirak Buarpung,
- 7 D.V.M., Ph.D. ⁴, Lin Li, M.D., Ph.D. ⁴, Ifeyinwa V. Asiodu, Ph.D. R.N. ⁵, Nadav Ahituv,
- 8 Ph.D.¹, Valerie J. Flaherman, M.D., M.P.H.², Stephanie L. Gaw, M.D., Ph.D. ^{4,7}
- 10 Author Affiliations

- ¹ Department of Bioengineering and Therapeutic Sciences, University of California, San
- Francisco, CA, 94158 and Institute for Human Genetics, University of California, San
- 13 Francisco, California, United States of America.
- ² Department of Pediatrics, University of California, San Francisco, California, United
- 15 States of America.
- ³Division of Pediatric Infectious Diseases and Global Health, University of California,
- 17 San Francisco, California, United States of America.
- ⁴ Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and
- 19 Reproductive Sciences, University of California San Francisco, California, United States
- 20 of America.

⁵ Department of Family Health Care Nursing, University of California, San Francisco, 21 California, United States of America. 22 ⁶ Department of Laboratory Medicine, University of California, San Francisco, California, 23 24 United States of America. ⁷ Center for Reproductive Sciences, Department of Obstetrics, Gynecology, and 25 Reproductive Sciences, University of California San Francisco, California, United States 26 of America. 27 28 ⁸ Department of Medicine, University of California, San Francisco, California, United States of America. 29 Corresponding author: Stephanie L. Gaw- Division of Maternal-Fetal Medicine, 30 Department of Obstetrics, Gynecology, and Reproductive Sciences, University of 31 California San Francisco, 513 Parnassus Ave, HSE16, Box 0556, San Francisco, CA 32 94143. Phone: 415.476.0535. Email: Stephanie.Gaw@ucsf.edu 33 34 35 **Conflict of interest:** 36 The authors have declared that no conflict of interest exists. 37 38

39

Abstract:

41

Background: Data regarding the rate of adverse effects observed in the lactating 42 mother-infant dyad and their immune response to COVID-19 mRNA vaccination during 43 lactation are needed to inform vaccination guidelines. 44 **Methods:** From a prospective cohort of 50 lactating individuals who received mRNA-45 based vaccines for COVID-19 (mRNA-1273 and BNT162b2), blood and milk samples 46 47 were collected prior to first vaccination dose, immediately prior to 2nd dose, and 4-10 weeks after 2nd dose. Symptoms in mother and infant were assessed by detailed 48 guestionnaires. Anti-SARS-CoV-2 antibody levels in blood and milk were measured by 49 Pylon 3D automated immunoassay and ELISA, and PEGylated proteins in milk were 50 measured by ELISA. Blood samples were collected from a subset of infants whose 51 mothers received the vaccine during lactation or pregnancy (4-15 weeks after mothers' 52 2nd dose). 53 Results: No severe maternal or infant adverse effects were reported in this cohort. Two 54 mothers and two infants were diagnosed with COVID-19 during the study period. 55 Vaccine-related products, PEGylated proteins, were not found at significant levels in 56 57 milk after vaccination. After vaccination, levels of anti-SARS-CoV-2 IgG and IgM 58 significantly increased in maternal plasma and there was significant transfer of anti-SARS-CoV-2-Receptor Binding Domain (anti-RBD) IgA and IgG antibodies to milk. Milk 59 60 IgA levels after 2nd dose were negatively associated with infant age. Anti-SARS-CoV-2 IgG antibodies were not detected in the plasma of infants whose mothers were 61 62 vaccinated during lactation.

- 63 Conclusions: COVID-19 mRNA vaccines generate robust immune responses in
- plasma and milk of lactating individuals without severe adverse effects reported.

Introduction:

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

An important benefit of human milk is the presence of IqA and IqG antibodies that provide passive immunity to the infant (1, 2). Anti-SARS-CoV-2 antibodies are present in milk from lactating women who were infected with SARS-CoV-2 (3, 4) or who received COVID-19 mRNA vaccines (5–8). Specifically, high titers of anti-SARS-CoV-2 IgG were reported after vaccination(6). The function of these antibodies in protection of infants against COVID-19 is not fully understood. Recently, work has demonstrated that murine pups can transfer IgG antibodies from ingested milk to their bloodstream, via enteric Fc receptors (9); however, this phenomenon has not been demonstrated in humans. To better understand the function and distribution if human milk antibodies and infant immunization after maternal vaccination, we examine anti-SARS-CoV-2 antibody levels in infant stool and blood. In addition, information is lacking on the potential adverse effects of COVID-19 vaccination on lactating mothers and their infants, who were excluded from initial clinical trials of mRNA vaccination (10). Many breastfeeding individuals have concerns regarding the potential effects on their infant due to the lack of data, leading to delayed vaccination or early cessation of breastfeeding (11). In this study, we examined blood and milk samples from lactating mothers who received a COVID-19 mRNA vaccine and their infants for the presence of anti- SARS-CoV2 antibodies, presence of PEGylated protein vaccine products, and self-reported vaccinerelated symptoms in order to address the gap of knowledge regarding vaccination efficacy and safety in this population.

Results:

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Participant characteristics. During the study period, 50 participants answered all study questionnaires, provided blood and/or milk samples, had an infant up to 18 months old and were included in this analysis. Two infants were diagnosed with COVID-19 during this study (**Table S1**, infant of participants 1 and 2). One mother reported that her infant had mild symptoms 1 week after the 2nd dose; this infant's vaccinated mother had a negative test at the time of the infant's positive PCR test. A second infant had positive plasma anti-SARS-CoV-2 IqG and IqA, despite the mother receiving the vaccine postpartum and reported no known prior COVID-19 infection. The mother's plasma was subsequently found to be positive to antibodies against SARS-CoV-2 nucleocapsid protein, indicating a likely natural asymptomatic SARS-CoV-2 infection (further details in **Table S1**). Two mothers were positive for COVID-19 and are presented in **Table S1** (participants 2 and 3); they were excluded from further analysis of symptomatology. Cohort characteristics are presented in **Table 1**. Twenty-seven female participants (mean age 35.7 years (± 3.9)) received the BNT162b2 vaccine (Pfizer, 56%), and 21 received the mRNA-1237 (Moderna, 44%). The mean infant age at mother's 1st dose was 5 months (±3.9). All mothers continued to feed their infants with milk at the time of the 2nd vaccination, and all except one continued up to the time of follow up sample collection (4-10 weeks after 2nd dose). There were no significant differences in maternal or infant characteristics by vaccine manufacturer.

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

Post vaccination symptoms. Self-reported symptoms after each vaccine dose are presented in **Table 2**. Fever, chills, headache, joint pain, muscle aches or body aches, and fatique or tiredness were reported by significantly more participants after the 2nd dose than after the 1st dose (Table 2). All 21 participants (100%) who received the mRNA-1237 vaccine reported injection site symptoms, while only 21 (78%) of 27 BNT-162b2 recipients reported injection site symptoms (p=0.02) (**Table 2**). Two mothers reported slightly less milk production in the first 24-72 hours after vaccine doses (Table 2). With respect to infant symptoms, 12% of mothers reported at least one symptom after the 1st maternal vaccine dose (primarily gastrointestinal symptoms and sleep changes), and none reported an infant symptom after the 2nd dose (Table 3). In summary, no severe adverse effects for mothers or nursing infants were reported in this cohort after vaccination, and reported symptoms resolved up to 72 hours after vaccination. **PEG detection in human milk.** Polyethylene glycol (PEG) is present in the lipid nanoparticles of the mRNA-based vaccines, and was reported to cause allergic reaction after vaccination in rare cases (12, 13). To address concerns about vaccine components passing to milk after vaccination, we performed ELISA assays to measure PEG-ylated proteins levels in milk after vaccination from 13 participants. PEG-ylated proteins were measured in milk samples collected before the vaccine, and at various time points post-vaccination (from 24 hours after 1st dose to 2 weeks after 2nd dose). Pre-vaccine PEG-ylated proteins levels did not significantly differ from PEG-ylated proteins levels at any post-vaccine time point in either paired or unpaired comparisons (Figure 1).

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

Anti-SARS-CoV-2 antibody levels in blood and milk samples after vaccination. We analyzed blood and milk samples from lactating individuals for anti-SARS-CoV-2 antibodies to measure immune response after vaccination. Maternal blood anti-SARS-CoV-2 IgM and IgG antibodies increased significantly after the 1st dose (Figure 2). Anti-SARS-CoV-2 IgM levels were not significantly higher 4-10 weeks after the 2nd dose compared to samples collected after dose 1 (on the day of the 2nd dose) (Figure 2A). In contrast, anti-SARS-CoV-2 IgG levels increased significantly after the 2nd dose (P value <0.0001) when compared to samples collected immediately prior to the 2nd dose (Figure 2B). There was no significant difference in blood antibody levels between participants who received the mRNA-1237 compared to the BNT-162b2 vaccine after dose 2. We found significantly higher levels of IgA antibodies specific to SARS-CoV-2 RBD protein in human milk samples collected after the 1st dose of both BNT-162b2 and mRNA-1237 vaccines (Figure 3A and 3B). There was no significant increase in milk anti-RBD IgA after the 2nd vaccination as compared to after dose 1 (Figure 3A and **3B**). Twelve individuals (25%. BNT-162b2 n=7; mRNA-1237 n=5) did not have detectable levels of anti-RBD IgA after either the 1st or 2nd dose (infants age at 1st dose range 1-11 months). Milk anti-RBD IgG levels increased after the 1st dose of vaccine and increased further after the 2nd dose (Figure 3C and 3D). There were no significant differences in milk anti-RBD IgG levels between women who received BNT-162b2 (Figure 3C) and mRNA-1237 (Figure 3D). These findings suggest that mRNA vaccine results in a robust immune response leading to increased anti SARS-CoV-2 antibody levels in blood, but also in milk during lactation.

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

Correlations between antibody levels, participant characteristics, and symptoms. In order to better understand the differences in antibody responses between individuals in our cohort, we performed multiple correlation tests to determine whether IgG and IgA antibodies levels correlated with timing of sample collection after vaccination (range 4-10 weeks after 2nd dose), infant age at time of vaccination, or maternal BMI (Table S2). Milk IgA (but not IgG) levels declined significantly as the infant age at time of vaccination increased (Figure 4A and 4B). There was no significant correlation between IgG and IgA levels and either the length of time after 2nd dose or maternal BMI (Table S2 and S3). The levels of IgG and IgA antibodies induced in milk were significantly correlated after 1st dose (Figure 4C), but not after the 2nd dose (Figure **4D**). There was no correlation between the anti SARS-CoV-2 IqG levels in blood and milk after 1st dose (Figure 4E), but there was a positive correlation between levels at 4-10 weeks after 2nd dose (Figure 4F). Plasma levels of anti-SARS-CoV-2 IqG are not detectable in infants after maternal vaccination during lactation. Although maternal IgG antibodies have been shown in multiple studies to transfer to the infant in utero, there are little data to suggest that milkderived antibodies are similarly transferred to the infant blood circulation during breastfeeding. To investigate whether passive immunity is conferred to the infant's blood after maternal vaccination during lactation, we analyzed infant blood samples from mothers who were vaccinated after delivery (n=8) and compared to infant blood samples form mothers who were vaccinated against COVID-19 during pregnancy (n=2). Blood samples were collected from these 10 infants (5 male, 5 female) at 61 days to 1 year of age (Table S4). Plasma was tested for the presence of anti-SARS-CoV-2 IgG

and IgM and anti-RBD IgA. We evaluated infant blood samples collected at time frame of 4-15 weeks after 2nd dose as this time point corresponded to high anti-SARS-CoV-2 IgG levels in mothers' blood and milk (Figure 2 and 3). No antibodies were detected in the blood of nursing infants born to mothers who were vaccinated postpartum (Figure 5), despite high IgG levels in maternal blood and milk. In contrast, infants born to mothers who received both doses of vaccine during pregnancy had detectable plasma anti-SARS-CoV-2 lgG levels at follow-up (infant age range 61-65 days, 125-129 days after maternal dose 1) (Figure 5). None of the follow-up infant blood samples (from the lactation or pregnancy cohorts) had detectable levels of anti-RBD IqA antibodies. These results demonstrate that vaccination during lactation induces anti-SARS-CoV-2 antibodies in human milk, but only vaccination during pregnancy and not lactation provides additional transfer of anti-SARS-CoV-2 antibodies to the infant blood. We also investigated whether ingested antibodies could survive passage through the infant gastrointestinal tract by testing infant stool for anti-SARS-CoV-2 antibodies after vaccination (Figure S1) in one mother-infant dyad. We found that IgG (but not IgA) was detected in infant stool samples and were correlated with maternal milk anti-SARS-CoV-2 IgG levels.

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

Conclusion:

Our study provides one of the first detailed reports on patient symptoms and antibody responses of the COVID-19 mRNA vaccines in lactating mothers. We found that the rates of reported symptoms were similar to the CDC report from the V-Safe registry(14) but higher than described in the clinical trials, although we do not have a non-lactating comparison group. Importantly, there were no significant side effects noted in the infants of mothers vaccinated during breastfeeding. Comparing the mRNA vaccines made by current manufacturers, we found that lactating individuals may experience more vaccine-related side effects after mRNA-1237 compared to BNT-162b2 vaccine; however, no differences in immune response were observed between those vaccines.

It has recently been shown in a few studies that vaccine mRNA is not present in milk samples after vaccination(15, 16), or is only detected in very low levels in some cases(17), providing reassurance that risks of exposure to the breastfed infant are minimal. This study adds to the evidence that vaccine components are minimally transferred to human milk. We found no significant increase in milk PEG-ylated protein concentrations at various time points after vaccine administration in a subset of samples analyzed in our cohort. We did observe one sample with higher ratio of PEG-ylated proteins 24 hours post vaccination (**Figure 1**, patient 030). This sample had PEG-ylated protein levels equivalent to 2.8µl/ml vaccine. However, we cannot confirm that the increased PEG in this single sample was from the COVID-19 vaccine, as PEG exposure may also be from other sources, such laxatives or ibuprofen. There was no increase in protein PEG-ylation ratio after 2nd dose in the same individual, and no unusual symptoms were reported in either the mother or her infant. Larger studies are needed to

increase our understanding of transfer of PEG into human milk, and potential effects after ingestion by the infant. Although expert consensus states there is minimal or no potential risk for the infant from maternal COVID-19 vaccination(18, 19), the minor symptoms that were reported (sleep changes and gastrointestinal symptoms) should be further investigated in future studies to determine if they are related to vaccination. Our findings also suggest that administration of maternal mRNA-based vaccine during lactation did not lead to a detectable immune response in the infant blood, which further suggests that the vaccine is not transferred to the infant via milk and cannot trigger infant immune responses via that route.

We also demonstrate that COVID-19 mRNA vaccination induces significant increases in anti-SARS-CoV-2 IgM and IgG levels in lactating mothers' blood.

Consistent with previous studies that showed IgM levels plateaued 28 days after COVID-19 infection (20), our results also demonstrated that dose 2 did not induce significantly higher levels of IgM than was is observed after dose 1. In contrast, maternal blood IgG levels increased by 6-fold after the 2nd dose (compare to the levels after the 1st dose), highlighting the importance of the 2nd dose to boost the antibody response (21).

Due to the lack of data about vaccination during pregnancy, many pregnant individuals were initially denied access to, declined, or were recommended to delay vaccination until after pregnancy. As such, many mothers have waited until after delivery to receive the vaccine. Although mothers vaccinated during lactation transferred antibodies to their infant through milk, which is an important component of mucosal immunity for the baby, there was no passive transfer of antibodies to the infant

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

bloodstream, as occurs if the mother is vaccinated during pregnancy. Correlates of infant immune protection to COVID-19 are not yet well understood, however passive *in utero* transfer of IgG to the infant is important in the prevention of a number of infections including pertussis and influenza (22–24). Passively-transferred milk-derived IgA likely provides partial mucosal immune protection in infants, as breastfeeding is associated with lower risk of infections associated with mucosal defense, especially against respiratory infections (25–27).

Two nursing infants in our cohort were infected with COVID-19 during the study (one a week post maternal 2nd dose, and the second one between 1st and 2nd maternal vaccine), indicating that milk antibodies cannot fully protect against SARS-CoV-2 infection, especially at the time before full immune response is achieved in the vaccinated mother, typically 2-3 weeks after the booster dose (Figure 2D). Further studies are needed to determine the degree of protection conferred by IgA and IgG anti-SARS-CoV-2 antibodies that are present in milk. Interestingly, we demonstrated for the first time that anti-SARS-CoV-2 RBD IgG antibodies are detectable in stool samples collected 4 and 8 weeks post maternal vaccine (Figure S1), which suggests that milkderived antibodies can persist in the infant gastrointestinal tract and provide protection against viral infection via the digestive system(28). Further studies evaluating the additive benefit of both transplacentally-derived maternal IgG, as well as milk-derived IgA and IgG are needed to determine protection against COVID-19 in early infancy. Our findings demonstrate the importance of determining the optimal timing of vaccine administration to confer maximal protection against COVID-19 in infancy.

Twenty-five percent of women in our cohort had no detectable levels of anti-RBD IgA in their milk after vaccination. Similar findings were reported in other studies (5, 6), suggesting that production and transfer efficiency vary between individuals. Our analysis showed a negative correlation between infant age and milk anti-RBD IgA levels, which might explain some of the variation in milk IgA levels observed between different individuals. Ten out of the 12 participants who had no detectable anti-RBD IgA, had infants older than 5.5 months at the time of sample collection. Further studies are needed to investigate the relationship between infant age, breastfeeding exclusivity, milk IgA antibodies, and optimal timing of vaccination during lactation.

Strengths of our study include the prospective design and comprehensive symptom reporting by the vaccinated participants. We also report on longitudinal follow-up of infant immune responses, which has not been previously described. Furthermore, we included both BNT162b2 and mRNA-1273 vaccines and compared responses between the two vaccine manufacturers. Limitations include the small sample size, and that not all samples were able to be collected from all infant participants.

In summary, our study reports that no severe adverse effects were noted in lactating individuals or their breastfeeding infants after COVID-19 mRNA vaccination. We demonstrated that human milk confers passive immunity to the infants, primarily through mucosal immunity in the gastrointestinal tract provided by IgA and IgG in milk. These results are important evidence to aid in counseling lactating individuals on the safety and efficacy of the COVID-19 mRNA vaccines, and the potential benefits to both the mother and infant.

Methods:

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

Study approval and study population. The institutional review board of the University of California San Francisco approved the study. Written, informed consent was obtained from all study volunteers in the COVID-19 Vaccine in Pregnancy and Lactation (COVIPAL) cohort study from December 2020 to June 2021. Eligible participants were actively pregnant or lactating, planning to receive any COVID-19 vaccine, and willing to donate blood and/or milk samples. Clinical data collection. Clinical data on vaccine side effects were collected through an online questionnaire that was sent to participants 21 days or more after each vaccine administration. Questionnaires were distributed using REDCap. Sample collection. Maternal blood and milk samples were collected at three time points: 1) up to 1 day before the 1st dose (pre-vaccine); 2) on the day of and prior to administration of the 2nd dose (after 1st dose); and between 4-10 weeks after the 2nd dose (after 2nd dose). In some cases, additional milk samples were collected up to 31 days before the 1st dose, 24 hours after each dose, and weekly for up to 4 weeks after the 2nd dose. Infant blood was collected by heel stick by trained study staff at 5-15 weeks after 2nd maternal vaccination. Milk processing. Fresh human milk samples were self-collected by participants into sterile containers at several time points before, during, and after vaccination. Milk samples were either collected immediately by the study staff or frozen by mothers in their home freezer as soon as possible after pumping. Samples were kept on ice during

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

transport from home to the lab for processing. Milk was aliquoted and stored in -80°C until analyzed. Measurement of SARS-CoV-2 specific IqM and IqG in plasma samples. Whole blood was collected into tubes containing EDTA. Plasma was isolated from whole blood by centrifugation and immediately cryopreserved at -80°C until analysis. Anti-SARS-CoV-2 plasma IgM and IgG antibodies were measured using the Pylon 3D automated immunoassay system(29) (ET Healthcare, Palo Alto, CA). In brief, quartz glass probes pre-coated with either affinity-purified goat anti-human IgM (IgM capture) or Protein G (IgG capture) were dipped into diluted plasma samples, washed, and then dipped into the assay reagent containing both biotinylated, recombinant spike protein receptor binding domain (RBD) and nucleocapsid protein (NP). After washing, the probes were incubated with Cy®5-streptavidin (Cy5-SA) polysaccharide conjugate reagent, allowing for cyclic amplification of the fluorescence signal. The background-corrected signal of SARS-CoV-2 specific antibodies was reported as relative fluorescent units (RFU). IgM and IgG measurements greater than 50 RFU were considered positive RFUs. Measurement of IgA and IgG by ELISA assay in milk. After thawing, milk fat was separated by cold centrifugation (10,000g for 10 min, 4°C). Milk supernatant samples were diluted 1:2 in sample diluent buffer and were plated in duplicate on a 96-well plate containing S1 spike protein RBD (Ray-Biotech, GA, USA, IEQ-CoVS1RBD-IgG-1 and IEQ-CoVS1RBD-IgA-1). For IgA assays, samples were also plated in duplicate on a second 96-well plate coated with human albumin to account for non-specific binding. OD values for albumin were subtracted from the OD values for RBD. Each plate

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

contained seven anti-RBD standards and one blank negative control. The mean absorbance of each sample was captured on an ELISA plate reader at 450 nm. Background values (blank negative control) were subtracted from the albumin and RBD plates. Standard controls were used to create a standard curve and determine the level of anti-RBD IgA and IgG in unit/ml. Measurement of Polyethylene Glycol (PEG) in human milk by ELISA. Milk supernatant was diluted 1:8 with the provided sample buffer and analyzed by PEGylated protein ELISA kit (Enzo, Farmingdale, NY, USA). Seven wells of each plate were loaded with serial dilutions (1:2) of mRNA-1273 or BNT162b2 to generate the standard curve for each vaccine (Figure 1A). In addition, vaccines were inoculated into human milk samples at three different concentrations (33µl/ml, 3.3µl/ml and 0.33µl/ml) and were analyzed separately to ensure the ability of the kit to detect the vaccine PEGylated components in milk samples (Figure 1B). Prism 9 (v 9.1.2) was used to interpolate vaccine concentration in the samples based on OD values, using a sigmoidal, four parameters logistic curve. A mean of pre-vaccine milk PEG concentration was calculated based on 13 pre-vaccine samples analyzed. Results are presented as a ratio of sample concentration divided by the mean pre-vaccine milk PEG concentration. Statistics: All data analyses were conducted using Stata statistical software (v14, College Station, TX). Descriptive statistics included frequencies for categorical variables, and means, standard deviations, medians, and ranges for continuous variables. Group differences in categorical variables were analyzed using Fisher's exact test, and group differences in continuous variables were analyzed using Mann-Whiney U tests. McNemar tests were used to evaluate differences in symptom frequencies after

each vaccine dose. Spearman correlations was used to assess the magnitude of associations between continuous variables. Non-parametric tests were used to accommodate non-normal distributions and small group sizes.

Author contribution:

YG designed the study, conducted experiments, acquired data, analyzed data, and was lead author of the manuscript. MP designed the study, conducted experiments, acquired data, analyzed data, assisted with editing and writing the manuscript. AC recruited participants, acquired data, and assisted with editing and writing the manuscript. CG analyzed data, conducted statistical analysis assisted with editing the manuscript. AHBW providing reagents and acquired data. UJ collected samples and conducted experiments. CYL recruited participants and collected samples. VJG, LW, SB, LL collected and process samples. EB collected and processed samples and assisted with editing the manuscript. IVA assisted with study and questionnaires design and editing and writing the manuscript. NA supervised the study and assisted in writing the manuscript. SLG and VJF designed and supervised the study and assisted in writing the manuscript.

References:

- 1. Labayo HKM et al. Norovirus-specific immunoglobulin A in breast milk for protection
- against norovirus-associated diarrhea among infants.. EClinicalMedicine
- 379 2020;27:100561.
- 2. Sadeharju K et al. Maternal antibodies in breast milk protect the child from
- enterovirus infections. *Pediatrics* 2007;119(5):941–946.
- 382 3. Fox A et al. Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in
- Human Milk[published online ahead of print: 2020]; doi:10.1016/j.isci.2020.101735
- 4. Demers-Mathieu V et al. Difference in levels of SARS-CoV-2 S1 and S2 subunits-
- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human
- 386 milk. *J. Perinatol.* 2020;1–10.
- 5. Perl SH et al. SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19
- Vaccination of Breastfeeding Women. *JAMA* 2021;(19):2013–2014.
- 6. Fox A, Norris C, Amanat F, Zolla-Pazner S, Powell RL. The vaccine-elicited
- immunoglobulin profile in milk after COVID-19 mRNA-based vaccination is IgG-
- dominant and lacks secretory antibodies. *medRxiv* 2021;2021.03.22.21253831.
- 7. KELLY JC et al. Anti-SARS-CoV-2 antibodies induced in breast milk after Pfizer-
- 393 BioNTech/BNT162b2 vaccination. Am. J. Obstet. Gynecol. 2021;0(0).
- 394 doi:10.1016/j.ajog.2021.03.031

- 8. Gray KJ et al. COVID-19 vaccine response in pregnant and lactating women: a
- 396 cohort study. *Am. J. Obstet. Gynecol.* 2021;0(0). doi:10.1016/j.ajog.2021.03.023
- 9. Zheng W et al. Microbiota-targeted maternal antibodies protect neonates from enteric
- infection. *Nature* 2020;577(7791):543–548.
- 10. Krause PR, Gruber MF. Emergency Use Authorization of Covid Vaccines Safety
- and Efficacy Follow-up Considerations. N. Engl. J. Med. 2020;383(19):e107.
- 401 11. Hall S. COVID vaccines and breastfeeding: what the data say. *Nature*
- 402 2021;594(7864):492–494.
- 12. Sellaturay P, Nasser S, Ewan P. Polyethylene Glycol–Induced Systemic Allergic
- 404 Reactions (Anaphylaxis). *J. Allergy Clin. Immunol. Pract.* 2021;9(2):670–675.
- 405 13. Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene
- 406 glycol (PEG) the culprit?. BJA Br. J. Anaesth. 2021;126(3):e106.
- 14. Shimabukuro TT et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in
- 408 Pregnant Persons. N. Engl. J. Med. [published online ahead of print: April 21, 2021];
- 409 doi:10.1056/nejmoa2104983
- 15. Mattar CN et al. Title page Addressing anti-syncytin antibody levels, and fertility and
- breastfeeding concerns, following BNT162B2 COVID-19 mRNA vaccination. *medRxiv*
- 412 2021;2021.05.23.21257686.
- 16. Golan Y et al. Evaluation of Messenger RNA From COVID-19 BTN162b2 and

- 414 mRNA-1273 Vaccines in Human Milk. *JAMA Pediatr*. [published online ahead of print:
- 415 July 6, 2021]; doi:10.1001/jamapediatrics.2021.1929
- 416 17. Ming J et al. BNT162b2 vaccination induces SARS-CoV-2 specific antibody
- 417 secretion into human milk with minimal transfer of vaccine mRNA. medRxiv
- 418 2021;2021.04.27.21256151.
- 18. STAFFORD IA, PARCHEM JG, SIBAI BM. The COVID-19 vaccine in pregnancy:
- risks benefits and recommendations. *Am. J. Obstet. Gynecol.* [published online ahead
- 421 of print: January 30, 2021]; doi:10.1016/j.ajog.2021.01.022
- 19. Craig AM, Hughes BL, Swamy GK. Coronavirus disease 2019 vaccines in
- 423 pregnancy. *Am. J. Obstet. Gynecol. MFM* 2021;3(2):100295.
- 20. Liu X et al. Patterns of IgG and IgM antibody response in COVID-19 patients.
- 425 Emerg. Microbes Infect. 2020;9(1):1269–1274.
- 426 21. Polack FP et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N.
- 427 Engl. J. Med. 2020;383(27):2603-2615.
- 22. Dabrera G et al. A case-control study to estimate the effectiveness of maternal
- pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013.
- 430 Clin. Infect. Dis. 2015;60(3):333–337.
- 23. Amirthalingam G et al. Effectiveness of maternal pertussis vaccination in England:
- 432 An observational study. *Lancet* 2014;384(9953):1521–1528.

- 24. Puck JM, Glezen WP, Frank AL, Six HR. Protection of infants from infection with
- influenza A virus by transplacentally acquired antibody. J. Infect. Dis. 1980;142(6):844–
- 435 849.
- 436 25. Wright AL, Holberg CJ, Martinez FD, Morgan WJ, Taussig LM. Breast feeding and
- lower respiratory tract illness in the first year of life. Group Health Medical Associates...
- 438 *BMJ* 1989;299(6705):946–949.
- 26. Tarrant M, Kwok M, Lam T, Epidemiology GL-, 2010 undefined. Breast-feeding and
- childhood hospitalizations for infections. *JSTOR*
- 27. Oddy WH et al. Breast feeding and respiratory morbidity in infancy: A birth cohort
- 442 study. Arch. Dis. Child. 2003;88(3):224–228.
- 28. Ma C, Cong Y, Zhang H. COVID-19 and the Digestive System. Am. J.
- 444 *Gastroenterol.* 2020;115(7):1003–1006.
- 29. Lynch KL et al. Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome
- 446 Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. Clin.
- 447 Infect. Dis. 2021;72(2):301–308.

These studies were supported by the Marino Family Foundation (to M.P), the National Institutes of Health (NIAID K23AI127886 to M.P. and NIAID K08AI141728 to S.L.G.), the Krzyzewski Family (to S.L.G.), the Weizmann Institute of Science -National Postdoctoral Award Program for Advancing Women in Science (to Y.G.), the International Society for Research In Human Milk and Lactation (ISRHML) Trainee Bridge Fund (to Y.G.), and of the Human Frontier Science Program (to Y.G.).

Figures:




Figure 1: Detection of vaccine PEG in human milk samples. A) different vaccine concentrations were used to generate a standard curve of OD (Y axis) vs. vaccine concentration (X axis). Vaccine concentrations in each sample were interpolated based on Sigmoidal, four-parameter logistic (4PL) curve. B) mRNA-1273 and BNT-162b2 vaccines were inoculated separately from pre-vaccine milk samples and were used to ensure the assay's sensitivity to detect the vaccine PEG components in milk samples. C) Values shown in heat map are the ratio of calculated PEG concentration in each

sample to average PEG concentration in all pre-vaccine milk samples. No significant differences were observed between samples collected at any of the post vaccine (PV) time points and the pre-vaccine samples (paired and unpaired two-tailed t-tests). Y axes represent time of sample collection, as hours (h) or weeks (w) Post vaccine 1 (PV 1), or Post vaccine 2 (PV 2).




Figure 2: Elevated levels of plasma anti-SARS-CoV2 antibodies in COVID-19 mRNA vaccinated lactating individuals. Anti-SARS-CoV2 IgM (A) and IgG (B) levels in plasma of lactating individuals post COVID-19 mRNA vaccine (RFU- relative fluorescent units, positive cut-off >50 RFU). After 1st dose samples were collected on the day of the second vaccine, and after 2nd dose samples were collect 4-10 weeks post 2nd dose. Asterisks represent p-values: *= p-value <0.05, **= p-value <0.01, ****= <0.001, ****= <0.0001 as determined by unpaired Mann-Whitney test.




Figure 3: Elevated levels of milk anti-SARS-CoV2 IgA antibodies in COVID-19 mRNA vaccinated lactating individuals. Milk samples from individuals receiving BNT-162b2 (n=27) (A) and mRNA-1273 (n=21) (B) anti- SARS-CoV2 vaccines were analyzed for anti-SARS-CoV2 IgA antibodies using ELISA at various time points as indicated on the X axis. After 1st dose samples were collected on the day of the second vaccine, and after 2nd dose samples were collect 4-10 weeks post 2nd dose. Milk anti-SARS-CoV2 IgG levels were measured using ELISA in milk samples from individuals receiving BNT-162b2 (n=27) (C) or mRNA-1273 (n=21) (D). Asterisks represent p-values: *= p-value <0.05, **= p-value <0.01, ***= <0.001 as determined by unpaired Mann-Whitney test.




Figure 4: Correlations between milk antibodies, blood antibodies and infant age. Two-tailed Spearman correlation was used to correlate milk IgA (A) and IgG (B) levels (Y axis) and infant age (X axis) 4-10 weeks after the 2nd dose administration (n=30). In addition, two-tailed Spearman correlation was used to correlate milk IgG (Y axis) and milk IgA levels (X axis) on the day of 2nd dose administration(C), 21-28 days after 1st dose (n=35) and and 4-10 weeks after 2nd dose (D). We also tested correlation between milk (Y axis) and maternal plasma (X axis) IgG levels at day of 2nd dose (E) and 4-10 weeks after the 2nd dose administration (F) (n=30).




Figure 5: Transfer of anti-SARS-CoV2 IgG from mother to infant. IgG levels were measured in blood samples of infants and mothers 61 days to 1 year postpartum, 61-129 days after 1st maternal vaccine administration. Maternal and infant samples were collected in the same week (except in one case in which the maternal sample was collected 18 days prior to the infant sample). X axis represents the time at which the mother received the 1st dose: during pregnancy (pink), or after delivery (red). (RFU-relative fluorescent units, dashed line represents positive cut-off >50 RFU). Sample characteristics and individual antibodies levels are present in **Table S4**.

Tables:

512

513

Table 1. Sample characteristics overall and by vaccine manufacturer

Sample Characteristics	Full Cohort	BNT162b2	mRNA-1237
	(n=48, 100%)	(n=27, 56%)	(n=21, 44%)
Maternal characteristics			
Maternal age, years			
Median (min, max)	35 (27, 46)	35 (30, 45)	35 (27, 46)
Race/ethnicity, % (n)			
Asian	31% (15)	30% (8)	33% (7)
Black or African American	2% (1)	4% (1)	0% (0)
White/Caucasian	59% (28)	55% (15)	62% (13)
Other (Arab)	2% (1)	0% (0)	5% (1)
More than 1 race/ethnicity (White+Latina/Asian/Middle Eastern)	6% (3)	11% (3)	0% (0)
Highest level of education completed			
Some college	2% (1)	0% (0)	5% (1)
College graduate	17% (8)	19% (5)	14% (3)
Advanced degree	81% (39)	81% (22)	81% (17)
Work in health care?	()	()	, , ,
Yes, providing direct patient care	58% (28)	52% (14)	67% (14)
Yes, but not in direct patient care	19% (9)	15% (4)	24% (5)
No	23% (11)	33% (9)	9% (2)
Pre-Pregnancy Body Mass Index	, ,		
Median (min, max)	23.4 (19.1,	23.4 (19.1,	22.8 (19.6,
, , ,	37.5)	35.9)	37.5)
Number of children	,	,	,
1	40% (19)	41% (11)	38% (8)
2	46% (22)	41% (11)	52% (11)
3	12% (6)	15% (4)	10% (2)
4	2% (1)	3% (1)	0% (0)
Duration of most recent pregnancy, weeks	270 (1)	070 (1)	070 (0)
Median (min, max)	39.0 (33.9, 41.1)	39.1 (33.9, 41.0)	39.0 (37.4, 41.1)
Infant characteristics	,	,	,
Infant age at maternal 1st dose, months			
Median (min, max)	4.7 (0.1, 17.2)	4.8 (0.2, 15.2)	4.6 (0.1, 17.2)
Sex, % (n)	,	- /	,
Male	60% (29)	67% (18)	52% (11)
Female	40% (19)	33% (9)	48% (10)

Exclusively breastfeeding (and no solids)			
Yes	23% (11)	22% (6)	24% (5)
No	77% (37)	78% (21)	76% (16)
Days after vaccine that symptoms			
were assessed			
Dose 1			
Mean (SD)	78.7 (31.8)	78.3 (35.4)	79.2 (27.4)
Median (min, max)	81 (18, 154]	78 (18, 154)	86 (26, 117)
Dose 2			
Mean (SD)	59.6 (25.1)	62.6 (28.3)	55.8 (20.2)
Median (min, max)	58.5 (28,	57 (29, 133)	60 (28, 89)
,	133)	,	

- Note: None of the characteristics above differed significantly by vaccine manufacturer.
- Abbreviations: Standard deviation (SD), minimum (min), maximum (max)

Table 2: Symptoms after each vaccine dose

Symptoms	F	ull Coho	ort:	Afte	er 1st dose	,	Afte	r 2nd dose	•
	1st dose	2nd dose	P- value ^a	BNT162b2	mRNA- 1237	p- value ^b	BNT162b2	mRNA- 1237	p- value ^b
	4.000	n=48	1 0.10.0	n=27	n=21	- Carolo	n=27	n=21	
Injection site symptoms,	% (n)					1			
Any injection site	88%	88%	>0.99	78% (21)	100%	0.02	78% (21)	100%	.02
symptoms	(42)	(42)			(21)			(21)	
Pain	88%	85%	0.71	78% (21)	100%	0.02	78% (21)	95%	0.12
	(42)	(41)			(21)			(20)	
Redness	4%	10%	0.08	0% (0)	10% (2)	0.19	4% (1)	19% (4)	0.15
	(2)	(5)						, ,	
Swelling	17%	17%	>0.99	7% (2)	29% (6)	0.12	11% (3)	24% (5)	0.27
_	(8)	(8)						, ,	
Itching	4%	4%	>0.99	4% (1)	5% (1)	>.99	4% (1)	5% (1)	>.99
•	(2)	(2)			, ,				
Rash around injection	2%	4%	0.32	0% (0)	5% (1)	0.44	0% (0)	10% (2)	0.19
site	(1)	(2)						, ,	
Generalized symptoms, 9	% (n)								
Any general symptoms	48%	92%	<0.001	44% (12)	52%	0.77	85% (23)	100%	0.12
	(23)	(44)			(11)			(21)	
Fever	12%	62%	<0.001	19% (5)	5% (1)	0.21	52% (14)	76% (16)	0.13
	(6)	(30)							
Chills	8%	48%	<0.001	11% (3)	5% (1)	0.62	37% (10)	62%	0.14
	(4)	(23)						(13)	
Headache	21%	67%	<0.001	11% (3)	33% (7)	0.08	56% (15)	81%	0.07
	(10)	(32)						(17)	
Joint pain	8%	31%	0.002	7% (2)	10% (2)	>0.99	30% (8)	33% (7)	>0.99
-	(4)	(15)							
Muscle/body aches	21%	69%	<0.001	30% (8)	10% (2)	0.15	59% (16)	81%	0.13
	(10)	(33)						(17)	

Fatigue or tiredness	44%	81%	<0.001	41% (11)	48%	0.77	67% (18)	100%	0.003
	(21)	(39)			(10)			(21)	
Nausea	4%	12%	0.10	4% (1)	5% (1)	>0.99	7% (2)	19% (4)	0.38
	(2)	(6)							
Vomiting	0%	0%		0% (0)	0% (0)		0% (0)	0% (0)	
	(0)	(0)							
Diarrhea	4%	4%	>0.99	4% (1)	5% (1)	>0.99	0% (0)	10% (2)	0.19
	(2)	(2)							
Abdominal pain	2%	0%	0.32	0% (0)	5% (1)	0.44	0% (0)	0% (0)	
	(1)	(0)							
Rash not near injection	0%	0%		0% (0)	0% (0)		0% (0)	0% (0)	
site	(0)	(0)							
Lump/swelling in breast	0%	2%	0.32	0% (0)	0% (0)		4% (1)	0% (0)	>0.99
(same side as injection)	(0)	(1)							
Lump/swelling in breast	0%	0%		0% (0)	0% (0)		0% (0)	0% (0)	
(opposite side as	(0)	(0)							
injection)									
Mastitis	2%	0%	0.32	0% (0)	5% (1)	0.44	0% (0)	0% (0)	
	(1)	(0)							
Decrease in milk supply	2%	2%	>0.99	0% (0)	5% (1)	0.44	0% (0)	5% (1)	0.44
	(1)	(1)							

^a McNemar's test; ^b Fisher's Exact test

Table 3. Infant symptoms reported after maternal vaccination (write-in only)

INFANT SYMPTOMS	% (n)	Vaccine
After 1st vaccine dose		
None / no changes / blank	88% (42)	
"My baby seemed a little tired."	2% (1)	BNT162b
"He started pooping a lot! And it was more sour smelling diarrhea like poops. I don't know if there is any correlation"	2% (1)	BNT162b
"It could have been a fluke, but both my infant and I slept through the night for the first time the night after I received the 1st dose of the vaccine."	2% (1)	BNT162b
"He had some diaper rash, but likely unrelated"	2% (1)	BNT162b
"Rash on the face / worsening of baby acne"	2% (1)	mRNA- 1237
"Disrupted sleep, waking at night when he usually doesn't. More fussy than normal."	2% (1)	mRNA- 1237
After 2nd vaccine dose		
None / no changes / blank	100% (48)	

Table S1. Participants testing positive for SARS-CoV-2 during the study period

Participants testing positive for SARS-CoV-			
2			
Participant ID:	1	2	3
Mother positive for SARS-CoV-2	No	Yes	Yes
Infant positive for SARS-CoV-2	Yes	Yes	No
Other people in the household diagnosed	Yes	N/A	No
Time of diagnosis	1 week after	N/A	10 day before
	2nd dose		1st dose
Baby exclusively breastfed	No	Yes	No
Maternal blood IgG (RFU)			
On the day of 2nd dose	244	5503	N/A
4 weeks after 2nd dose	2558	5290	N/A
Infant blood IgG (RFU)			
4 weeks after 2nd vaccine dose	N/A	1928	N/A
Infant blood IgA (U/ml)			
4 weeks after 2nd vaccine dose	N/A	122	N/A
Milk anti-RBD IgG levels (U/ml)			
Pre-vaccine	N/A	55	7.3
On the day of 2nd dose	246	2653	323
4 weeks after 2nd dose	375	2834	250
Maternal blood positive for anti SARS-	N/A	Samples	N/A
CoV2-N-protein antibodies		collected on	
		day of 2nd	
		dose and 5	
		weeks after	
		2nd dose were	
		positive.	
Maternal injection site symptoms			
Reported after 1st vaccine dose:	Pain	Pain, Itching	None
Reported after 2nd vaccine dose:	Pain	None	Pain

Maternal generalized symptoms			
Reported after 1st vaccine dose:	None	None	None
Reported after 2nd vaccine dose:	Fever, Chills, Muscle aches or body aches, Fatigue or tiredness	Fever, Chills, Fatigue or tiredness	Fatigue or tiredness
Baby symptoms			
After 1st dose	None	None	None
after 2nd dose:	None	Less active. Feverish.	None

Table S2. Correlations between antibody levels and timing of samples in relation to childbirth and vaccine

Austile adiana austranaus la trusca le aigne	N.I.	Casar		
Antibodies and sample types being	N	Spearman correlations		
correlated			ations	
		rho	р	
Samples collected after 1st dose				
IgG in maternal blood and	24			
Time from childbirth to		0.38	0.07	
collection				
Time from 2nd dose to sample		-0.11	0.59	
IgG in breast milk and	35			
Time from childbirth to sample		05	0.75	
Time from 2nd dose to sample		-0.12	0.47	
lgA in breast milk and	38			
Time from childbirth to sample		-0.18	0.28	
Time from 2nd dose to sample		0.12	0.45	
Samples collected after dose 2				
IgG in maternal blood and	32			
Time from childbirth to sample		0.01	0.92	
Time from 2nd dose to sample		-0.34	0.05	
IgG in breast milk and	44			
Time from childbirth to sample		0.04	0.75	
Time from 2nd dose to sample		0.21	0.16	
IgA in breast milk and	43			
Time from childbirth to sample		-0.35	0.02	
Time from 2nd dose to sample		-0.17	0.27	

Table S3. Antibody levels were not significantly correlated with maternal BMI

Correlation between maternal BMI and the		Spearman correlations		
following antibody levels:	n	rho	р	
After 1st dose				
IgG in maternal blood	24	071	.74	
IgG in milk	35	029	.87	
IgA in milk	38	204	.22	
4-10 weeks after 2nd dose				
IgG in maternal blood	32	.113	.54	
IgG in milk	44	101	.51	
lgA in milk	43	.115	.46	

Table S4. Follow up maternal and infant blood samples characteristics and anti-SARS-CoV2 IgG levels

Participant #	Participan t Cohort:	Infant sex	Infant age at sample date (months):	Infant age at 1st dose (months)	Time since 1st dose until infant sample collection (days)	Infant anti- SARS- CoV2 IgG antibodies (RFU):	Maternal anti- SARS- CoV2 IgG antibodi es (RFU):	Vaccine type:
1	Lactating	Female	0-3	0-3	84	6	2768	mRNA- 1237
2	Lactating	Male	0-3	0-3	58	2	1791	mRNA- 1237
3	Lactating	Female	0-3	0-3	64	0	1638	BNT162b2
4	Lactating	Female	3-6	0-3	67	4	5028	mRNA- 1237
5	Lactating	Female	3-6	0-3	61	6	3449	mRNA- 1237
6	Lactating	Male	6-9	3-6	81	7	3292	mRNA- 1237
7	Lactating	Male	9-12	6-9	103	2	1574	mRNA- 1237
8	Lactating	Male	>12	9-12	62	3	3418	BNT162b2
9	Pregnant	male	0-3	-2	129	812	271	BNT162b2
10	Pregnant	female	0-3	-2	125	1604	288	mRNA- 1237

Note: negative values in infant age represent days before delivery. RFU>50 considered as positive value.